Late Breaking Original Research
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Introduction:
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but concerns linger over the generalizability of their safety due to the underrepresentation of patients with poor performance status (PS) in randomized controlled trials (RCTs). This study aims to assess the safety of ICIs in this population by comparing the incidence of immune-related adverse events (irAEs) between patients with good PS (ECOG 0–1) and poor PS (ECOG 2+)
Research Question or Hypothesis:
Does the use of ICIs result in a higher incidence of irAEs in patients with poor PS?
Study Design:
A retrospective analysis of real-world patient data.
Methods:
Patients` data who received ICIs in Qatar between 2015 and 2020 were examined. Out of 254 identified patients, medical records were scrutinized to determine irAE incidence and characteristics in those with poor versus good PS.
Results:
Out of the 254 patients, 184 (72%) had good PS, while 70 (28%) exhibited poor PS. Median ages were 55 and 61 for good and poor PS groups, respectively (table1). In the good PS group, 94 patients (51.1%) developed irAEs, compared to 37 patients (52.9%) in the poor PS group (p-value 0.89). The incidence of irAEs were comparable and statistically insignificant between both groups (table2). However, cardiac irAEs were significantly more frequent in patients with poor PS [3 (1.6%) vs. 7 (10%), p-value 0.015]. Thoracic and gastrointestinal cancer diagnoses were common among patients who developed irAEs in both groups. A total of 16 fatal irAEs were recorded, with 9 occurring in the good PS group and 7 in the poor PS group.
Conclusion:
This study reveals a comparable irAE incidence in cancer patients with good and poor PS, except for a higher frequency of cardiac irAEs in the poor PS group. Future survival data comparing poor and good PS patients are crucial for a comprehensive understanding.
Presenting Author
Nabil Elhadi Omar BSc Pharm, BCOP, PharmD, PhD(C)National Centre for Cancer Care & Research- Hamad Medical Corporation
Authors
Hebatalla Afifi BSc Pharm, PharmD
NCCCR
Aya Alasmar BSc Pharm, PharmD
National center for cancer care and research , Hamad Medical Corporation, Doha, Qatar
Afnan Alnajjar BSc Pharm, PharmD
National center for cancer care and research, Hamad Medical Corporation, Doha, Qatar
Maria Benkhadra Pharm D
NCCCR
Amaal Gulied Pharm D
NCCCR
Anas Hamad PhD, MSc, RPh
HMC
Farah Jibril BSc Pharm, PharmD
National Center for Cancer Care and Research
Sahar Nasser BSc Pharmacy, RPH, ASHP PGY-1
HMC
Rawan A. Dawoud BSc Pharm, PharmD
National center for cancer care and research , Hamad Medical Corporation, Doha, Qatar
Shereen Elazzazy PharmD, MBA, BSc Pharm
Hamad Medical Corporation
Mohamed S. Elkhatim MD
National center for cancer care and research , Hamad Medical Corporation, Doha, Qatar
Mohamed Saad PharmD, BCPS, BCCCP
Al-Wakra Hospital, Hamad Medical Corporation
Arwa Osama Sahal BSc Pharm, PharmD
National Centre for Cancer Care & Research- Hamad Medical Corporation